News: Endo Health Solutions Inc (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

39.04USD
11:29am EDT
Price Change (% chg)

$-0.01 (-0.03%)
Prev Close
$39.05
Open
$39.01
Day's High
$39.10
Day's Low
$38.66
Volume
65,086
Avg. Vol
526,816
52-wk High
$39.90
52-wk Low
$25.01

Search Stocks
Select another date:

Thu, Jun 27 2013

DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan

NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.

Endo Health to slash 15 percent jobs, looks to sell some assets

- Endo Health Solutions Inc said it plans to cut about 15 percent of its workforce and explore strategic alternatives for some assets as the company looks to cut costs ahead of generic competition for two of its biggest drugs.

UPDATE 1-Endo Health to slash 15 pct jobs, looks to sell some assets

* Cuts FY adj profit view to $4.10-$4.40/shr from $4.40-$4.70/shr

Endo Health to cut 15 pct jobs, explore options for two units

June 5 - Endo Health Solutions Inc said it plans to cut about 15 percent of its global workforce and will explore strategic alternatives for two units as the company looks to reduce about $325 million in annual operating expenses.

FDA denies approval to Endo's testosterone drug again

- The Food and Drug Administration has for the third time refused approval to Endo Health Solutions Inc's injectable testosterone drug Aveed, pressing for a still better plan to manage the risks associated with the drug.

FDA allows generic forms of Endo Health's Opana ER painkiller

- The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard on pain drugs to prevent their abuse.

UPDATE 1-FDA allows generic forms of Endo Health's Opana ER painkiller

May 10 - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard on pain drugs to prevent their abuse.

Panel divided over safety of Endo's testosterone drug

- An advisory panel to the U.S. Food and Drug Administration was sharply divided on Thursday over whether a drug made by Endo Health Solutions Inc can safely be prescribed for men with low testosterone.

UPDATE 1-US panel divided over safety of Endo's testosterone drug

April 18 - An advisory panel to the U.S. Food and Drug Administration was sharply divided on Thursday over whether a drug made by Endo Health Solutions Inc can safely be prescribed for men with low testosterone.

U.S. FDA panel deadlocked over Endo's testosterone drug

April 18 - An advisory panel to the U.S. Food and Drug Administration was deadlocked over whether the agency should approve Endo Health Solutions Inc's experimental drug to treat low testosterone in men.

Select another date:
Search Stocks